Huntington's Disease Treatment Market Forecasts from 2023 to 2028

Huntington’s disease treatment market was valued at US$840.142 million in 2021.

Huntington’s disease treatment marketis anticipated to grow at a steady pace. Due to the organism's aberrant response against its own tissue, autoimmune disease results in the breakdown of normal immunological homeostasis. Inflammation, autoantibodies, and self-reactive T cells are typically impacted by autoimmune disorders. Potential autoimmune illnesses are difficult to diagnose since no one laboratory test can provide an accurate diagnosis of the condition. The diagnosis can aid with the treatment of autoimmune disease patients and can help with prognosis or identifying the degree of organ involvement or damage.

MARKET DRIVERS:

Increased prevalence of diseases and cutting-edge drug development to bolster growth.

The growth of Huntington's disease treatment market is attributed to several factors, including an increase in the prevalence of the disease and a rise in the demand for cutting-edge drug types for treating Huntington's symptoms. Clinical trials and a robust drug pipeline are other Huntington's disease treatment industry trends that are anticipated to support the Huntington's disease treatment market's forecasted expansion.

Huntington's disease treatment industryis expanding because of both an increase in the prevalence of the condition and a rise in demand for cutting-edge disease treatments.

Growing prevalence of autoimmune diseases

The burden of autoimmune disorders is increasing globally, and there is a growing awareness of health issues and diseases, which increases the need for diagnostics for early disease diagnosis and propels the market's expansion. The American Autoimmune Related Disease Association (AARDA), for instance, marks the month of March each year as Autoimmune Disease Awareness Month (ADAM). AARDA is dedicated to the elimination of autoimmune diseases, the reduction of suffering, and the socioeconomic effect of autoimmunity. In February 2021, the American Kidney Fund (AKF) introduced a new patient-focused education and awareness campaign on the kidney disease lupus nephritis.

Increasing patients with rheumatoid arthritis

An autoimmune condition called rheumatoid arthritis (RA) primarily targets the synovial tissues in the joints. Most of the disease's victims are older people. The segment's growth is also greatly influenced by the ageing population and technological improvements.

The prevalence of rheumatoid arthritis among the old population has increased along with the burden of the geriatric population, which is what is driving the market's expansion. For instance, the World Population Prospect, 2022 estimates that there will be 771 million people worldwide who are 65 or older in 2022, and that number would rise to 994 million by 2030 and 1.6 billion by 2050.

Increasing clinical trials

The Huntington’s disease market is expanding because of an increase in clinical research efforts for various drug development procedures. An investigational monoclonal antibody called ANX005 is being developed by Annexon, Inc., and targets aberrant C1q activity in complement-mediated neurodegenerative illnesses including Huntington's Disease. It is given intravenously (IV) and is intended to inhibit the whole classical complement system, including C1q. Additionally, the business began a phase 2 clinical trial of ANX005 for the treatment of HD patients in 2020. As a possible HD treatment, stem cell therapy is also attracting attention. Cellavita is currently researching stem cell treatment, CELLAVITA-HD, in phase 2/ 3 ADORE-DH study in partnership with AzidusPharma.

Increasing R&D activities

Throughout the forecast period, rising R&D activities and product development are also anticipated to aid in Huntigton’s disease treatment market's growth. For instance, in April 2021, an IND application for Voyager Therapeutics Inc.'s VY-HTT, a gene therapy candidate intended to treat Huntington's disease was approved by the US FDA. The goal of the treatment is to stop the huntingtin gene from being expressed to slow the spread of the illness. Similarly, uniQure NV reported clinical results for the first four patients included in the lower-dose group of its ongoing Phase I/II clinical study of AMT-130 in December 2021. The gene therapy project AMT-130 is intended to treat Huntington's disease.

Disease-modifying therapies are predicted to grow.

Disease-modifying therapies are anticipated to see the fastest rate of Huntington’s disease treatment market growth throughout the anticipated time frame. This is a result of increasing research and development for disease-modifying medicines as well as a surge in demand for cutting-edge items like gene therapy and stem cell treatment. Positive government initiatives, such as the U.S. FDA's Fast Track Designation for accelerating the registration process, are anticipated to support the industry in the approaching years. For instance, in October 2023, the U.S. FDA approved Sage Therapeutics' drug SAGE-718 as a potential treatment for Huntington's disease.

North America is anticipated to become a significant marketplace.

North America’s Huntington’s disease market share is brought on by the high disease burden, rising healthcare costs, technology developments, proactive government measures, and growing patient knowledge of Huntington's disease treatment options. Throughout the projection period, businesses are anticipated to ramp up their R&D and product development efforts. For instance, PTC Therapeutics began a Phase 2 study in the United States in April 2022 to examine PTC518, a potential therapy for Huntington's disease. The two-part PIVOT-HD experiment will be carried out in clinical settings all around the world. Participants will be randomly randomized to receive either a placebo or PTC518 (around three months) before being followed for 12 weeks.

Asia Pacific is predicted to grow at a robust pace during the forecast period

The Asia Pacific Huntington's disease treatment market is anticipated to see substantial growth. The region's market is anticipated to rise because of an increase in the number of government programs aimed at enhancing population health. The market for treating Huntington's illness is, however, crowded, which could prevent its expansion in this area. To stop them from launching a generic version of Austedo on the market, for instance, Teva Pharmaceutical Industries Ltd. announced the patent dispute settlement of AUSTEDO® (deutetrabenazine) patent with Aurobindo.

Market Key Developments

• In September 2022, Teva Pharmaceutical established the Honestly HD website.to assist individuals in better understanding chorea, one of Huntington's Disease's (HD) most noticeable and treatable symptoms, and how to talk to their doctor about retaining independence.
• In January 2022, To evaluate Tominersen in a fresh Phase 2 trial for the treatment of Huntington's disease, Ionis Pharmaceuticals Inc. established a collaboration with Roche.

Segmentation:

By Drug

• Tetrabenazine
• Deutetrabenazine
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Treatment Channel

• Public
• Private

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others